Asset Details
Do you wish to reserve the book?
Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
Do you wish to request the book?
Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
2018
Overview
Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV), two members of the
Pneumoviridae
family, account for the majority of severe lower respiratory tract infections worldwide in very young children. They are also a frequent cause of morbidity and mortality in the elderly and immunocompromised adults. High levels of neutralizing antibodies, mostly directed against the viral fusion (F) glycoprotein, correlate with protection against either hRSV or hMPV. However, no cross‐neutralization is observed in polyclonal antibody responses raised after virus infection or immunization with purified F proteins. Based on crystal structures of hRSV F and hMPV F, we designed chimeric F proteins in which certain residues of well‐characterized antigenic sites were swapped between the two antigens. The antigenic changes were monitored by ELISA with virus‐specific monoclonal antibodies. Inoculation of mice with these chimeras induced polyclonal cross‐neutralizing antibody responses, and mice were protected against challenge with the virus used for grafting of the heterologous antigenic site. These results provide a proof of principle for chimeric fusion proteins as single immunogens that can induce cross‐neutralizing antibody and protective responses against more than one human pneumovirus.
Synopsis
Chimeric fusion (F) proteins bearing neutralizing epitopes of hRSV and hMPV offer the possibility of using a single immunogen to induce cross‐protective antibody responses against both viruses.
Postfusion‐stabilized hMPV F bearing antigenic site II of hRSV induced antibodies that neutralized hRSV and hMPV and protected against an hRSV challenge.
Prefusion‐stabilized hRSV F bearing antigenic site IV of hMPV also induced antibodies that cross‐neutralized hRSV and hMPV.
Graphical Abstract
Chimeric fusion (F) proteins bearing neutralizing epitopes of hRSV and hMPV offer the possibility of using a single immunogen to induce cross‐protective antibody responses against both viruses.
Publisher
Nature Publishing Group UK,EMBO Press,John Wiley and Sons Inc,Springer Nature
Subject
/ Antibodies, Neutralizing - immunology
/ Antigens
/ Children
/ Chimeras
/ EMBO19
/ EMBO23
/ Enzyme-linked immunosorbent assay
/ Epitopes
/ Humans
/ Metapneumovirus - drug effects
/ Metapneumovirus - immunology
/ Mice
/ Paramyxoviridae Infections - drug therapy
/ Paramyxoviridae Infections - immunology
/ Proteins
/ Recombinant Fusion Proteins - immunology
/ Recombinant Fusion Proteins - pharmacology
/ Respiratory Syncytial Virus Infections - drug therapy
/ Respiratory Syncytial Virus Infections - immunology
/ Respiratory Syncytial Virus, Human - drug effects
/ Respiratory Syncytial Virus, Human - immunology
/ Viral Fusion Proteins - immunology
/ Viral Fusion Proteins - pharmacology
/ Viruses
